Table of Content:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Prostate Cancer Market: By Treatment Type Market Trends, Size, and Future Outlook
- By Treatment Type Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Treatment Type Definitions, Technology Landscape
- By Treatment Type Market Drivers
- New product launches
- Technological advancements in treatment modalities
- Increasing prevalence of prostate cancer
- By Treatment Type Market Restraints
- High cost of targeted therapies
- Side effects associated with chemotherapy
Chapter 4. Prostate Cancer Market: By Distribution Channel Market Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- Increasing online sales of drugs
- Rising adoption of e-pharmacies
- Growth in e-commerce sector
- By Distribution Channel Market Restraints
i. Lack of physical evaluation of medicines
ii. Probability of fake drugs in online pharmacies
Chapter 5. Prostate Cancer Market: By Stage Market Trends, Size, and Future Outlook
- By Stage Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Stage Definitions, Technology Landscape
- By Stage Market Drivers
- Increasing prevalence of prostate cancer
- Growing geriatric population
- Advancements in diagnostic techniques
- By Stage Market Restraints
- Low awareness levels in developing regions
- High cost of diagnosis and treatment
Chapter 6. Prostate Cancer Market: By End User Market Trends, Size, and Future Outlook
- By End User Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By End User Definitions, Technology Landscape
- By End User Market Drivers
- Rising geriatric population
- Increasing investments in healthcare infrastructure
- Growing awareness about prostate cancer screening
- By End User Market Restraints
- Limited access to healthcare services in low-income countries
- Shortage of skilled healthcare professionals
Chapter 7. Prostate Cancer Market: By Region Market Trends, Size, and Future Outlook
- North America Market Size (US$), CAGR (%), and Forecast (2022-2030)
- North America Market Drivers
- High prevalence of prostate cancer
- Presence of key players
- Favorable reimbursement policies
- North America Market Restraints
- Costly treatment procedures
- Europe Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Europe Market Drivers
- Increasing spending on healthcare
- Rising awareness about prostate cancer screening
- Europe Market Restraints
- Stringent regulations
- Asia Pacific Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Asia Pacific Market Drivers
- Large target patient population
- Increasing government funding
- Asia Pacific Market Restraints
- Lack of awareness in rural areas
- Limited access to cancer care facilities
- Latin America Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Latin America Market Drivers
- Growing healthcare expenditure
- Increasing cancer research activities
- Latin America Market Restraints
- High cost of branded drugs
- Weak healthcare infrastructure in remote areas
- Middle East & Africa Market Size (US$), CAGR (%), and Forecast (2022-2030)
- Middle East & Africa Market Drivers
- Rising prevalence of prostate cancer
- Growing medical tourism
- Middle East & Africa Market Restraints
- Limited access to healthcare
- Lack of awareness among population
Chapter 8. Prostate Cancer Market: Competitive Landscape
- Johnson & Johnson
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Pfizer
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Astellas Pharma
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- AstraZeneca
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Bayer
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Bristol Myers Squibb
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Novartis
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Roche
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Merck
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Ipsen
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
Frequently Asked Questions
The Prostate Cancer market was valued at USD 9.7 billion in 2023.
Rising incidence of prostate cancer globally, Growing elderly male population, Advances in screening, diagnosis and treatment technologies, Higher healthcare expenditure and awareness, Strong product pipeline
High cost of therapeutic drugs and procedures, Reimbursement restrictions in developing markets, Adverse side effects of treatments, Low screening rates in developing countries
Hormone therapy drugs like LHRH agonists and anti-androgens are the leading segment, occupying over 40% of the prostate cancer therapeutics market currently. These drugs slow cancer progression by reducing testosterone levels.
Johnson & Johnson, Pfizer, Astellas Pharma, AstraZeneca, Bayer, Novartis, AbbVie, Sanofi, Bristol Myers Squibb, Roche, Merck, Ipsen, Ferring Pharmaceuticals, Takeda, Teva Pharmaceuticals, Janssen Biotech.
The market is projected to grow at a CAGR of 8.9% from 2023 to 2030. The market size is expected to reach US$ 17.7 billion by 2030.